Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 3/2003

01-08-2003 | Free Paper

Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer

Authors: Constantinos Constantinides, Andreas C. Lazaris, Konstantinos N. Haritopoulos, Dimitrios Pantazopoulos, Michalis Chrisofos, Aris Giannopoulos

Published in: World Journal of Urology | Issue 3/2003

Login to get access

Abstract

Gastrin releasing peptide (GRP) is a neuropeptide that has been suggested to play a role in the development of some malignancies. Our aim was: (1) to identify the expression of GRP in cancerous prostate glands, and (2) to correlate its expression to various pathological parameters and to the patient's clinical outcome. Using standard immunohistochemistry, we evaluated GRP expression in both biopsy and radical prostatectomy specimens from 30 patients with prostatic adenocarcinomas. GRP was expressed in 18 radical prostatectomy specimens (60%) and in 15 biopsies (50%). There was an association between positive immunoexpression of GRP, relapse (P=0.029) and advanced tumor stages (i.e. pT3, pT4) (P=0.049). In the respective biopsies, GRP immunostatus was similar to that observed in the subsequent radical prostatectomy specimens. GRP immunoexpression may be of some value as a diagnostic and prognostic marker. Patients whose pathology specimens demonstrate GRP immunopositivity should be closely monitored, since they appear to be at higher risk of disease progression and relapse.
Literature
1.
Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S (1998) Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate (Suppl 8):52–61
2.
Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M (1989) Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63:1714–1720
3.
Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H (1997) Synergistic activation of androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 32:106–114CrossRefPubMed
4.
De Vincentis G, Scopinaro F, Varvarigou A, Ussof W, Schillaci O, Archimandritis S, Leontiadis L,Corleto V, Longo F, Delle Fave G (2002) Phase I trial of technetium [LEU 13] bombesin as a cancer seeking agent. Possible scintigraphic guide for surgery? Tumori 88:28–30
5.
Gkonos PJ, Krongrad A, Roos BA (1995) Neuroendocrine peptides in the prostate. Urol Res 23:81–87PubMed
6.
Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, deVere White RW, Schröder FH, Coffey DS (1999) Future prospects in prostate cancer. Prostate 40:261–268CrossRefPubMed
7.
Hoosein NM, Logothetis CJ, Chung LW (1993) Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analogue RC160 on the invasive capacity of human prostatic carcinoma cells. J Urol 149:1209–1213PubMed
8.
Jongsma J, Oomen MHA, Noordzij MA, Romijn JC, van der Kwast TH, Schröder, van Steenbrugge GJ (2000) Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 42:34–44CrossRefPubMed
9.
Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59:1152–1159PubMed
10.
Nagakawa O, Ogasawara M, Fujii H (1998) Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett 133:27–33PubMed
11.
Nagakawa O, Ogasawara M, Murata J, Fuse H, Saiki I (2001) Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 8:65–70PubMed
12.
Nakopoulou L, Stefanaki K, Deliveliotis C, Lazaris AC, Kondothanasis D, Dimopoulos C (1996) Neuroendocrine differentiation and proliferation state estimation in the hyperplastic and neoplastic human prostate. J Urol Pathol 4:239–251
13.
Noordji MA, van Steenbrugge GJ, van der Kwast T, Schröder FH (1995) Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res 22:333–341PubMed
14.
Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K (2000) Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 44:172–180CrossRefPubMed
15.
Reile H, Armatis PE, Schally AV (1994) Characterization of high affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound125I-[Tyr4] bombesin by tumor cells. Prostate 25:29–38PubMed
16.
Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z (2000) Peptide analogs in the therapy of prostate cancer. Prostate 45:158–166CrossRefPubMed
17.
Sun B, Halmos G, Schally AV, Wang X, Martinez M (2000) Presence of receptors for bombesin/gastrin releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 42:295–303PubMed
18.
Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (2000) Tumors of the prostatic gland, seminal vesicles, male urethra and penis. In: Young RH, Srigley JR, Amin MB et al. (eds) Atlas of tumor pathology. AFIP, Washington DC, pp 1–30
19.
Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (2000) Carcinoma of the prostatic gland. In: Young RH et al. (eds) Atlas of tumor pathology, AFIP, Washington DC, pp 111–217
Metadata
Title
Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer
Authors
Constantinos Constantinides
Andreas C. Lazaris
Konstantinos N. Haritopoulos
Dimitrios Pantazopoulos
Michalis Chrisofos
Aris Giannopoulos
Publication date
01-08-2003
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 3/2003
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-003-0339-y

Other articles of this Issue 3/2003

World Journal of Urology 3/2003 Go to the issue

Free Paper

Role of positive urethrovesical feedback in vesical evacuation. The concept of a second micturition reflex: the urethrovesical reflex

Topic Paper

Continent bladder stoma

Topic Paper

A simple and reliable continent bladder stoma constructed from bladder wall

Topic Paper

Experience with different questionnaires in the management of patients with CP/CPPS: GPSS, IPSS and NIH-CPSI

Free Paper

Reconfigured colon segments as a ureteral substitute

Topic Paper

Evolution of endoscopic extraperitoneal radical prostatectomy (EERPE)—technical improvements and development of a nerve-sparing, potency-preserving approach